Trials / Conditions / Stage III Cutaneous Melanoma AJCC v7

Stage III Cutaneous Melanoma AJCC v7

20 registered clinical trials studyying Stage III Cutaneous Melanoma AJCC v7.

Status	Trial	Sponsor	Phase
Terminated	Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or NCT03425461	Jonsson Comprehensive Cancer Center	Phase 1
Active Not Recruiting	Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma NCT02965716	National Cancer Institute (NCI)	Phase 2
Withdrawn	Glembatumumab Vedotin, Nivolumab, and Ipilimumab in Treating Patients With Advanced Metastatic Solid Tumors Th NCT03326258	National Cancer Institute (NCI)	Phase 1 / Phase 2
Terminated	Dendritic Cell Therapy With Pembrolizumab for Metastatic or Unresectable Melanoma NCT03325101	Mayo Clinic	Phase 1 / Phase 2
Active Not Recruiting	Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery NCT03021460	Mayo Clinic	Phase 1
Active Not Recruiting	Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutate NCT02910700	M.D. Anderson Cancer Center	Phase 2
Active Not Recruiting	A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma NCT02339571	National Cancer Institute (NCI)	Phase 2 / Phase 3
Completed	Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or NCT02304458	National Cancer Institute (NCI)	Phase 1 / Phase 2
Completed	Genetically Modified Therapeutic Autologous Lymphocytes Followed by Aldesleukin in Treating Patients With Stag NCT01740557	M.D. Anderson Cancer Center	Phase 1 / Phase 2
Active Not Recruiting	Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma NCT01955460	M.D. Anderson Cancer Center	Phase 1
Active Not Recruiting	Testing Two Different Treatment Schedules of Dabrafenib and Trametinib for Skin Cancer Which Has Spread NCT02196181	National Cancer Institute (NCI)	Phase 2
Terminated	Onalespib, Dabrafenib, and Trametinib in Treating Patients With BRAF-Mutant Melanoma or Solid Tumors That Are NCT02097225	National Cancer Institute (NCI)	Phase 1
Completed	A Vaccine (CDX-1401) With or Without a Biologic Drug (CDX-301) for the Treatment of Patients With Stage IIB-IV NCT02129075	National Cancer Institute (NCI)	Phase 2
Terminated	Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is NCT01940809	National Cancer Institute (NCI)	Phase 1
Completed	Tumor-Infiltrating Lymphocytes After Combination Chemotherapy in Treating Patients With Metastatic Melanoma NCT01807182	Fred Hutchinson Cancer Center	Phase 2
Completed	Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfun NCT01638533	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostat NCT01480154	National Cancer Institute (NCI)	Phase 1
Active Not Recruiting	Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma NCT01303341	National Cancer Institute (NCI)	Phase 1
Completed	Aldesleukin With or Without Ziv-Aflibercept in Treating Patients With Stage III-IV Melanoma That Cannot Be Rem NCT01258855	National Cancer Institute (NCI)	Phase 2
Active Not Recruiting	Ipilimumab With or Without Sargramostim in Treating Patients With Stage III or Stage IV Melanoma That Cannot B NCT01134614	National Cancer Institute (NCI)	Phase 2